Associations of pre-ICI corticosteroid use with pericardial disease and all-cause mortality
| N | Pericardial disease | All-cause mortality | |||
| Number | HR | Number | HR | ||
| Entire cohort | 126 | 42 | 65 | ||
| Corticosteroid prior to initiation of ICI | 12 | 7 | 2.11 (0.94 to 4.76), p=0.07 | 7 | 0.96 (0.44 to 2.12), p=0.93 |
| Higher dose (>0.7 mg/kg prednisone) | 7 | 5 | 2.56 (1.00 to 6.57), p=0.049 | 3 | 0.62 (0.19 to 1.98), p=0.42 |
| Lower dose (<0.7 mg/kg prednisone) | 5 | 2 | 1.33 (0.32 to 5.49), p=0.70 | 4 | 1.62 (0.59 to 4.48), p=0.35 |
Associations of pre-ICI corticosteroid use with pericardial disease and all-cause mortality in 42 patients who developed pericardial disease after ICI treatment vs 84 age-type and cancer-type matched control patients who did not develop pericardial disease after ICI treatment (design 2).
ICI, immune checkpoint inhibitor.